Oak Grove Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

Oak Grove Capital’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,005	Closed	-$307K	–	82
2021 Q4	$307K	Sell	5,005 -300	-6%	-$20.7K	0.05%	82
2021 Q3	$396K	Buy	5,305 +105	+2%	+$8.81K	0.09%	75
2021 Q2	$481K	Hold	5,200	–	–	0.11%	71
2021 Q1	$461K	Buy	+5,200	New	+$516K	0.13%	65

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Oak Grove Capital's ARKG Position: Q1 2022 in Review

Oak Grove Capital sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 5,005 shares — an estimated $307K sold.

Oak Grove Capital first reported a position in ARKG in Q1 2021 and held it in 4 quarters. The position peaked at $481K in Q2 2021. 388 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Oak Grove Capital reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Oak Grove Capital sold 5,005 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $307K.
Oak Grove Capital first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 4 quarters.
Oak Grove Capital's ARK Genomic Revolution ETF position peaked at $481K in Q2 2021.
388 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Oak Grove Capital's 13F filing for Q1 2022, filed 10 May 2022.